Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial-Reference-Cited by-同舟云学术

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial

Published:2021-04 Issue:4 Volume:8 Page:e254-e266
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Sharman Jeff P,Brander Danielle M,Mato Anthony R,Ghosh Nilanjan,Schuster Stephen J,Kambhampati Suman,Burke John M,Lansigan Frederick,Schreeder Marshall T,Lunin Scott D,Zweibach Alexander,Shtivelband Mikhail,Travis Patrick M,Chandler Jason C,Kolibaba Kathryn S,Sportelli Peter,Miskin Hari P,Weiss Michael S,Flinn Ian W

Funder

TG Therapeutics

Publisher

Elsevier BV

Subject

Hematology

Reference28 articles.

1. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines;Hallek;Blood,2008

2. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia;Lin;Blood,2002

3. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype;Dicker;Leukemia,2009

4. Genomic aberrations and survival in chronic lymphocytic leukemia;Döhner;N Engl J Med,2000

5. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial;Stilgenbauer;Blood,2014

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruton tyrosine kinase inhibitor-related atrial fibrillation and its implications in the treatment of B-cell lymphoma;Frontiers in Cardiovascular Medicine;2024-07-26

2. Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia;JAMA Oncology;2024-07-11

3. Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-07-10

4. Current Approaches and Novel New Agents in the Treatment of Chronic Lymphocytic Leukemia;JCO Oncology Practice;2024-06-07

5. Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review;JAMA Network Open;2024-06-03